University of Tokyo, Research Center for Advanced Science and Technology, 4-6-1 Komaba, Meguro-ku, Tokyo, Japan 153-8904.
Nat Rev Drug Discov. 2010 Nov;9(11):867-82. doi: 10.1038/nrd3251. Epub 2010 Oct 29.
Understanding the factors that promote drug innovation is important both for improvements in health care and for the future of organizations engaged in drug discovery research and development. By identifying the inventors of 252 new drugs approved by the US Food and Drug Administration from 1998 to 2007 and their places of work, and also classifying these drugs according to innovativeness, this study investigates the contribution of different types of organizations and regions to drug innovation during this period. The data indicate that drugs initially discovered in biotechnology companies or universities accounted for approximately half of the scientifically innovative drugs approved, as well as half of those that responded to unmet medical needs, although their contribution to the total number of new drugs was proportionately lower. The biotechnology companies were located mainly in the United States. This article presents a comprehensive analysis of these data and discusses potential contributing factors to the trends observed, with the aim of aiding efforts to promote drug innovation.
了解促进药物创新的因素对于改善医疗保健以及从事药物发现研究和开发的组织的未来都非常重要。本研究通过确定 1998 年至 2007 年间美国食品和药物管理局批准的 252 种新药的发明者及其工作地点，并根据创新性对这些药物进行分类，调查了在此期间不同类型的组织和地区对药物创新的贡献。数据表明，最初在生物技术公司或大学发现的药物约占批准的具有科学创新性药物的一半，以及满足未满足医疗需求的药物的一半，尽管它们在新药总数中的比例相对较低。生物技术公司主要位于美国。本文对这些数据进行了全面分析，并讨论了观察到的趋势的潜在促成因素，旨在帮助促进药物创新的努力。
